Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Namenda Product Hopping Settlement Surpasses Most Recent DOJ Agreements

Executive Summary

Direct purchasers' $750m settlement with Allergan is at least the second involving product hopping claims; only one DOJ settlement surpassed this amount in the past year.

You may also be interested in...



DOJ Casting Wider Net In Pharma Kickback Probes

Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.

FTC's First Product Hopping Complaint Targets Safety Claims For Suboxone Film Formulation

Commission files complaint as it reaches $50m settlement with Reckitt Benckiser.

Legal Briefs: Courts On Exclusivity; Namenda ‘Hard Switch’ Deemed Coercive; Acorda Fights Bass Patent Petition

FDA’s active moiety rationale for denying Vascepa five years exclusivity is rejected by district court; Actavis strategy to protect Namenda franchise meets another hurdle; Acorda challenges ‘improper purpose’ of Bass IPR petition.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel